Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

The Survival of Childhood Acute Lymphoblastic Leukemia and its Related Factors Using Competing Risks Model: A Retrospective Study from 2011 to 2019 in Northwestern Iran

Document Type : Original Article(s)

Authors

1 Department of Pediatric Hematology, Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran

2 Department of Biostatistics, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran

3 Department of Pediatric, Urmia University of Medical Sciences, Urmia, Iran

4 Department of Biostatistics, Hamadan University of Medical Sciences, Hamadan, Iran

5 Solid Tumor Research center, Urmia University of Medical Sciences, Urmia, Iran

6 Department of Epidemiology, Student Research Committee, School of Public Health, Iran University of Medical Science, Tehran, Iran

7 Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: We aimed to evaluate the survival rate and define the prognostic factors in children with acute lymphoblastic leukemia (ALL).
Method: In this retrospective study, the data were extracted from the medical records of 176 children with ALL who referred to Motahari Hospital in Urmia from 2011 to 2019. Endpoints of overall survival study were event-free survival, disease-free survival, and recurrent mortality. Overall survival and disease-free survival were the time from diagnosis to death of any cause or recurrence. Event-free survival time was calculated as the distance from the date of diagnosis to the date of the last prevention with the first event. Non-recurrent mortality included all non-recurrent deaths. Data analysis was performed using a cause-specific hazard model.
Results: The mean age of the patients was 5.61 ± 3.56 years and the median of diagnosis of ALL to death was 3.47 ± 2.61 years. The 1-year, 3- year and 5-year probability of survival were 83.1%, 75.10%, and 68%, respectively. Sex, hemoglobin level, and hepatosplenomegaly were significant in univariate and multivariate analysis (P < 0.05).
Conclusion: The competing risks model was applied to identify the risk factors for all causes of death. The factors affecting the survival rate of patients in the model can be employed in making clinical decisions and proposing therapeutic protocols. Furthermore, it reduces the duration of response to therapy, thereby decreasing the rate of mortality in children.

Keywords

Full Text

How to cite this article:

Noroozi M, Khalkhali HR, Bahadori R, Omidi T, Ghazizadeh F, Hejazi S, et al. The survival of childhood acute lymphoblastic leukemia and its related factors using competing risks model: A retrospective study from 2011 to 2019 in northwestern Iran. Middle East J Cancer. 2022;13(3):531-42. doi: 10.30476/mejc.2022.88069.1455.

References
  1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. New Engl J Med. 2004;350(15):1535-48.doi: 10.1056/NEJMra023001.
  2. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943-55. doi: 10.1016/S0140-6736(12)62187-4.
  3. Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663-39.doi: 10.1200/JCO.2011.37.8018.
  4. Kahn J, Keegan T, Tao L, Abrahão R, Bleyer A, Viny A. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016;122(17):2723-30.
  5. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75.doi: 10.1016/S0140-6736(17)33326-3.
  6. Marwaha R, Kulkarni K, Bansal D, Trehan A. Pattern of mortality in childhood acute lymphoblastic leukemia: experience from a single center in northern India. J Pediatr Hematol Oncol. 2010;32(5):366-9.doi: 10.1097/MPH.0b013e3181e0d036.
  7. Lightfoot T, Johnston W,Simpson J, Smith A, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263-9.doi: 10.1016/j.ejca.2011.10.007.
  8. Ribeiro K, Lopes L, de Camargo B. Trends in childhood leukemia mortality in Brazil and correlation with social inequalities. Cancer. 2007;110(8):1823-31.
  9. Chatenoud L, Bertuccio P, Bosetti C, Levi F, Negri E, La Vecchia C. Childhood cancer mortality in America, Asia, and Oceania, 1970 through 2007. Cancer. 2010;116(21):5063-74. doi: 10.1002/cncr.25406.
  10. Kulkarni K, Arora R, Marwaha R. Survival outcome of childhood acute lymphoblastic leukemia in India: a resource-limited perspective of more than 40 years. J Pediatr Hematol Oncol.2011;33(6):475-9.doi: 10.1097/MPH.0b013e31820e7361.
  11. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-84. doi: 10.1038/leu.2009.257.
  12. Pui C, Pei D, Sandlund J, Ribeiro R, Rubnitz J, Raimondi S, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371-82.doi: 10.1038/leu.2009.252.
  13. Zand A, Imani S, Sa’adati M, Borna H, Ziaei R, Honari H. Effect of age, gender, bloodgroup on blood cancers types. Kowsar M J. 2010;15(2):111-4.
  14. Kleinbaum D, Klein M. Survival analysis: a self-learning approach. 2nded. New York: Springer Science & Business Media; 2007.
  15. Khalkhali HR, Gharaaghaji R, Valizadeh R, Kousehlou Z, Ayatollahi H. Ten years’ survival in patients with cervical cancer and related factors in West Azerbaijan Province: Using of cox proportion hazard model. Asian Pac J Cancer Prev. 2019;20(5):1345.doi: 10.31557/APJCP.2019.20.5.1345.
  16. Prentice R, Kalbfleisch J, Peterson A, Flournoy N, Farewell V, Breslow N. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-54.
  17. Grover G, Swain P, Ravi V. A competing risk approach with censoring to estimate the probability of death of HIV/AIDS patients on antiretroviral therapy in the presence of covariates. J Off Stat.2014;3(1):7-16.
  18. Haller B, Schmidt G, Ulm K. Applying competing risks regression models: an overview. Lifetime Data Anal. 2013;19(1):33-58.doi: 10.1007/s10985-012-9230-8.
  19. Sousa D, Ferrwira F, Felix F, Lopes M. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223-9.doi: 10.1016/j.bjhh.2015.03.009.
  20. Abdali F, Taghavi S, Vazifekhah S, Behzad MN, Attari MM. Effect of progesterone on latent phase prolongation in patients with preterm premature rupture of membranes. Acta Medica Iranica. 2017:772-8.
  21. Ziaei J. High frequency of acute promyelocytic leukemia in northwest Iran. Asian Pac J Cancer Prev. 2004;5(2):188-9.
  22. Akbarzadeh Baghban A, Hosseinifard H, Baghestani AR, Ahmadi S, Rezaei Tavirani M, Kokhaei P. Factors that affecting survival of patients with acute myeloid leukemia. [In Persian] Koomesh. 2016;17(3):596-602.
  23. Padilha S, Dos Santos Souza E, Matos M, Domino N. Acute myeloid leukemia:,survival analysis of patients at a university hospital of Paraná. Rev Bras Hematol Hemoter. 2015;37(1):21-7.doi: 10.1016/j.bjhh.2014.11.008.
  24. Dinner S, Liedtke M. Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2018;2018(1):9-15.doi: 10.1182/asheducation-2018.1.9.
  25. Jain T, Litzow M. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology Am SocHematol Educ Program. 2018;2018(1):25-34.doi: 10.1182/asheducation-2018.1.25.
  26. Roberts K. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;2018(1):137-45.doi: 10.1182/asheducation-2018.1.137.
  27. Hazar V, Karasu G, Uygun V, Akcan M, Küpesiz A, Yesilipek A. Childhood acute lymphoblastic leukemia in turkey:factors influencing treatment and outcome a single center experience. J Pediatr Hematol Oncol. 2010;32(8):317-22.doi: 10.1097/MPH.0b013e3181ed163c.
  28. Almasi-Hashiani A, Zareifar S, Hashemi-Teir A. Survival rate among children with acute lymphoblastic leukemia based on their relapse status in Shiraz Shahid Faghihi hospital during 2004-9. [In Persian] Feyz. 2012;16(3):248-53.
  29. Basta N, James P, Gomez-Pozo B, Craft A, McNally R. Survival from childhood cancer in Northern England, 1968–2005. Br J Cancer. 2011;105(9):1402-8.doi: 10.1038/bjc.2011.341.
  30. Feltbower R, Kinsey S, Richards M, Shenton G, Michelagnoli M, McKinney P. Survival following relapse in childhood haematological malignancies diagnosed in 1974–2003 in Yorkshire, UK. Br J Cancer. 2007;96(7):1147-52.doi: 10.1038/sj.bjc.6603667.
  31. Zareifar S, Almasi-Hashiani A, Karimi M, Tabatabaee SH, Ghiasvand R. Five-year survival rate of pediatric leukemia and its determinants. [In Persian] Koomesh. 2012;14(1):13-19.
Middle East Journal of Cancer
Volume 13, Issue 3 - Serial Number 51
July 2022
Pages 531-542
Files
Share
How to cite
Statistics